Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for quality of life in NAFLD with hyperammonemia and covert hepatic encephalopathy
jRCT1041230103Recruiting
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rifaximin in metabolic dysfunction-associated steatotic liver disease (MASLD), hyperammonemia and hepatic encephalopathy (HE). Primary endpoint: Change in SF-36 score. Started Sep 2023; status: recruiting.
02
Drugs
rifaximin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hyperammonemiahepatic encephalopathy (HE)
Beyond the preview
Go deeper on jRCT1041230103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041230103.